Clinical Trial Update: A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HyQvia and Gammagard Liquid (Kiovig) in adults with CIDP has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• Gammagard Liquid (intravenous immunoglobulin (IVIG) 10% solution)
• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2023-05-24